The Estrogen Receptor Joins Other Cancer Biomarkers as a Predictor of Outcome
Endometrial cancer, the most common gynecologic malignancy in the United States, is on the rise, and survival is worse today than 40 years ago. In order to improve the outcomes, better biomarkers that direct the choice of therapy are urgently needed. In this review, we explore the estrogen receptor...
| Main Authors: | , , , , , , , |
|---|---|
| Format: | Online |
| Language: | English |
| Published: |
Hindawi Publishing Corporation
2013
|
| Online Access: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3816067/ |